All Companies articles – Page 5
-
ArticleRVX-001: a universal vaccine to tackle antimicrobial resistance
Drug-resistant infections are on the rise, endangering global health. Neil Murray from ReNewVax explains how the company’s universal pneumococcal vaccine, RVX-001, could reduce antibiotic use and help curb antimicrobial resistance.
-
ArticleMaking science run at the speed of thought: the reality of AI in drug discovery – Part 1
Everyone talks about AI speeding up drug discovery, but Eric Ma explains why, without clean data and statistical discipline, it can actually do the opposite.
-
NewsScripta Therapeutics raises $12m to advance neurodegenerative research
Oxford-based techbio start-up Scripta Therapeutics has announced a $12 million seed funding round helping them to reshape conventional drug discovery.
-
ArticleResetting retinal networks with a gene-agnostic approach
What if treating blindness did not mean fixing a single faulty gene? Find out how modifier gene therapy is designed to protect vision by targeting broader retinal pathways.
-
ArticleDeep data not big data
Bigger isn’t always better. In drug discovery, Dr Michael Ritchie argues that the future belongs not to those with the most data, but to those who understand its biological depth.
-
NewsNasal HPV vaccine could replace surgery for cervical cancer
Japanese researchers have developed a nasal HPV vaccine that could offer a non-invasive, fertility-preserving alternative to surgery for cervical cancer.
-
ArticleAI and the future of biomarker analysis in early R&D
AI is transforming biomarker analysis in early drug discovery, revealing hidden biological patterns that improve target discovery, patient selection and trial design for more precise and predictive R&D.
-
NewsHow antibody-drug conjugates are improving gynaecological cancer outcomes
Antibody-drug conjugates (ADCs) are emerging as a breakthrough in the fight against gynaecological cancers, offering targeted treatment for cervical, ovarian and uterine tumours.
-
ArticleCircular RNA technology: the future of gene therapy
Pioneering circular RNA could redefine what the future of gene therapy looks like. Erik Digman Wiklund, CEO of Circio, shares how his company’s platform is enhancing gene expression and tackling toxicity challenges through smarter design and scientific collaboration.
-
NewsNext-gen MRI agents improve stability and effectiveness
Scientists have developed a new class of MRI contrast agents that are both more stable and 30 percent more effective than previous designs.
-
NewsUK Government announce plans to phase out animal testing for drugs
The UK government have announced a new strategy to phase out animal testing in scientific research, aiming to replace traditional experiments with innovative human-relevant methods such as organ-on-a-chip systems and AI analysis.
-
ArticleNasal drug delivery: the non-invasive future of treatment
Advances in formulation science and device technology are transforming nasal drug delivery, enhancing absorption, stability and patient adherence. This article examines the innovations driving its growth and highlights future applications ranging from systemic treatments to nose-to-brain therapies and vaccines.
-
NewsScientists use AI to create antibodies entirely from scratch
Scientists at the University of Washington’s Institute for Protein Design have used artificial intelligence to create antibodies entirely from scratch, a breakthrough that could reshape drug discovery.
-
ArticleBeyond weight loss: the gap in current drug development for obesity
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
-
NewsZuckerberg's Biohub announces AI-powered biology to accelerate drug discovery
The initiative combines cutting-edge artificial intelligence with large-scale biological data, with the aim to transform how new treatments, drugs and therapies are developed.
-
ArticleRecombinant KLK1: the next step in stroke and preeclampsia treatment
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to restore blood flow, improve endothelial function and address unmet needs in the treatment of stroke and preeclampsia.
-
ArticleInside ELRIG Drug Discovery 2025: automation, AI and human-relevant models
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
-
ArticleIL-2 and GLP-1 receptor agonist combination tackles neuroinflammation
Can targeting both regulatory and inflammatory pathways change how we treat neurodegenerative disease? Coya Therapeutics is testing that idea with its IL-2 and GLP-1 receptor agonist combination.
-
NewsNuclera expands into Australasia with Solve Scientific partnership
Cambridge-based biotech firm Nuclera has partnered with Solve Scientific Australia to expand access to its eProtein Discovery™ System across Australia and New Zealand.
-
ReportLab Automation: Where Discovery Scales
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.